These data, together with the notion that both IL1β and IFN-α themselves are key SASP factors,69,73,75,76 strongly support a scientific scenario where systemic inflammation strengthens the severity of COVID-19 in the elderly population, and is, therefore, a potential intervention target for COVID-19 treatment. This evidence concerns the gene IL1B and COVID-19.